rad140 rad140 rad140 is an investigational selective androgen receptor modulator (sarm) that is developed by radius health, inc. for use in androgen replacement therapy. it was licensed to ellipses pharmaceuticals in 2020. some of the potential benefits under investigation are for the treatment of conditions such as muscle wasting and bone loss. rad140identifiers iupac name 2-chloro-4--3-methylbenzonitrile cas number1182367-47-0pubchem cid44200882chemspider26387625unii4o87q44kncchemical and physical dataformulac20h16cln5o2molar mass393.83 g·mol−13d model (jsmol)interactive image smiles clc1=c(c#n)c=cc(=c1c)n((c)o)c2=nn=c(o2)c3=cc=c(c=c3)c#n inchi inchi=1s/c20h16cln5o2/c1-11-16(8-7-15(10-23)17(11)21)24-18(12(2)27)20-26-25-19(28-20)14-5-3-13(9-22)4-6-14/h3-8,12,18,24,27h,1-2h3/t12-,18+/m0/s1key:xmbuppievafyho-kpzwwzawsa-n clinical trials the first-in-human study was initiated in october of 2017 and completed in september 2020 in postmenopausal women with breast cancer. in early 2020 a single case report of drug-induced liver injury following use of rad 140 was published. animal studies rad 140 appears to be safer than testosterone replacement therapy (trt) in rats. rad 140 slightly increased lean muscle mass when used in primates, by targeting androgen receptors in skeletal tissue.